✦ LIBER ✦

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma

✍ Scribed by Hong Chang; Young Trieu; Xiaoying Qi; Wei Xu; Keith A. Stewart; Donna Reece

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 159 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2006.08.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of prolonged therapy with bortezo

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

✍ James R. Berenson; Sundar Jagannath; Bart Barlogie; David T. Siegel; Raymond Ale 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 334 KB

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Rapid early monoclonal protein reduction

Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression

✍ Jatin Shah; Joan Bladé; Pieter Sonneveld; Jean-Luc Harousseau; Keith Lantz; Anil 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

O21 A retrospective single-center experi

O21 A retrospective single-center experience with bortezomib-based therapy of relapsed and/or refractory multiple myeloma: survival results of our first 104 consecutive patients

✍ G. Mikala; A. Batai; I. Bodo; Z. Csukly; J. Dolgos; G. Halm; J. Janosi; B. Kapas 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Combined pegylated liposomal doxorubicin

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

✍ Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). I

Rapid response of plasmacytomas to lenal

Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma

✍ Toshihiro Fukushima; Takuji Nakamura; Haruka Iwao; Hisanori Umehara 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views